SEA Antagonizes the Imatinib-Meditated Inhibitory Effects on T Cell Activation via the TCR Signaling Pathway

The BCR-ABL kinase inhibitor imatinib is highly effective in the treatment of chronic myeloid leukemia (CML). However, long-term imatinib treatment induces immunosuppression, which is mainly due to T cell dysfunction. Imatinib can reduce TCR-triggered T cell activation by inhibiting the phosphorylat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guanming, Yan, Yuhui, Chen, Xiaohua, Lin, Chen, Li, Yangqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909973/
https://www.ncbi.nlm.nih.gov/pubmed/24524084
http://dx.doi.org/10.1155/2014/682010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909973/
https://www.ncbi.nlm.nih.gov/pubmed/24524084
http://dx.doi.org/10.1155/2014/682010

Ejemplares similares